Nikhil Lalwani, President and Chief Executive Officer, ANI Pharmaceuticals : Yes. So on your first question on the stat that Chris shared in his prepared remarks was that seventy percent of enrollments in July are for the which is enrollment as in new cases initiated were for the prefilled were written with prefilled syringe. So that's what we said about the prefilled syringe. And then the second, your question on gross to net, I think there's a modest upward pricing advantage on in terms of the whack of the prefilled syringe. I think that's what we'll comment.